Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1623PAZ

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	JAN 27	Source of Registration (SR) information in REGISTRY updated and searchable
NEWS	4	JAN 27	A new search aid, the Company Name Thesaurus, available in CA/CAplus
NEWS	5	FEB 05	German (DE) application and patent publication number format changes
NEWS	6	MAR 03	MEDLINE and LMEDLINE reloaded
NEWS	7	MAR 03	MEDLINE file segment of TOXCENTER reloaded
NEWS	8	MAR 03	FRANCEPAT now available on STN
NEWS	9	MAR 29	Pharmaceutical Substances (PS) now available on STN
NEWS	10	MAR 29	WPIFV now available on STN
NEWS	11	MAR 29	No connect hour charges in WPIFV until May 1, 2004
NEWS	12	MAR 29	New monthly current-awareness alert (SDI) frequency in RAPRA

NEWS EXPRESS	MARCH 31 CURRENT WINDOWS VERSION IS V7.00A, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 13 APRIL 2004
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 07:19:41 ON 19 APR 2004

=> FIL STNGUIDE

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'STNGUIDE' ENTERED AT 07:19:47 ON 19 APR 2004

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Apr 16, 2004 (20040416/UP).

=> FIL HOME

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.06	0.27

FILE 'HOME' ENTERED AT 07:19:51 ON 19 APR 2004

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.48

FILE 'REGISTRY' ENTERED AT 07:19:56 ON 19 APR 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 16 APR 2004 HIGHEST RN 676095-08-2
DICTIONARY FILE UPDATES: 16 APR 2004 HIGHEST RN 676095-08-2

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2004

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
Uploading C:\Examination Auxillary files\10076318\10076318 elected specie.str



chain nodes :
2 3 4 5 11 12 13 14 15 18 19 20 21 22 23 24 25 26 27 28 29 30
35 36 37

ring nodes :
1 6 7 8 9 10 16 17 31 32 33 34
chain bonds :
1-2 2-3 3-4 3-25 3-26 4-5 4-27 5-28 7-11 11-12 12-13 13-14 13-18 14-15
14-29 15-16 15-30 18-19 19-20 20-21 21-22 22-23 23-24 32-35 35-36 35-37

ring bonds :
1-6 1-10 6-7 7-8 8-9 9-10 16-17 16-34 17-31 31-32 32-33 33-34
exact/norm bonds :
1-2 2-3 12-13 13-14 13-18 14-15 14-29 15-16
exact bonds :
3-4 3-25 3-26 5-28 7-11 11-12 15-30 18-19 19-20 20-21 21-22 22-23 23-24
32-35 35-36 35-37
normalized bonds :
1-6 1-10 4-5 4-27 6-7 7-8 8-9 9-10 16-17 16-34 17-31 31-32 32-33 33-34

Match level :
1:Atom 2:CLASS 3:CLASS 4:CLASS 5:CLASS 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:Atom 17:Atom 18:CLASS
19:CLASS 20:CLASS 21:CLASS 22:CLASS 23:CLASS 24:CLASS 25:CLASS 26:CLASS
27:CLASS 28:CLASS 29:CLASS 30:CLASS 31:Atom 32:Atom 33:Atom 34:Atom
35:CLASS 36:CLASS 37:CLASS

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

```
=> search l1 sss sam
SAMPLE SEARCH INITIATED 07:20:37 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -      5 TO ITERATE

100.0% PROCESSED       5 ITERATIONS                                  0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:            5 TO      234
PROJECTED ANSWERS:               0 TO        0

L2            0 SEA SSS SAM L1

=> search l1 sss full
FULL SEARCH INITIATED 07:20:48 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -     53 TO ITERATE

100.0% PROCESSED      53 ITERATIONS                                  3 ANSWERS
SEARCH TIME: 00.00.01

L3            3 SEA SSS FUL L1

=> d scan

L3   3 ANSWERS   REGISTRY  COPYRIGHT 2004 ACS on STN
IN   Butanoic acid, 2-[3-[2-[heptyl[[[4-(1-methylethyl)phenyl]amino]carbonyl]am
     ino]ethyl]phenoxy]-2-methyl-, (2R)- (9CI)
MF   C30 H44 N2 O4

Absolute stereochemistry.
```




```
HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):3

L3   3 ANSWERS   REGISTRY  COPYRIGHT 2004 ACS on STN
IN   Propanoic acid, 2-[3-[2-[heptyl[[[4-(1-methylethyl)phenyl]amino]carbonyl]a
     mino]ethyl]phenoxy]-2-methyl- (9CI)
MF   C29 H42 N2 O4
```



L3 3 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Butanoic acid, 2-[3-[2-[heptyl[[[4-(1-methylethyl)phenyl]amino]carbonyl]amino]ethyl]phenoxy]-2-methyl- (9CI)
MF C30 H44 N2 O4



ALL ANSWERS HAVE BEEN SCANNED

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	155.84	156.32

FILE 'CAPLUS' ENTERED AT 07:21:12 ON 19 APR 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 19 Apr 2004 VOL 140 ISS 17
FILE LAST UPDATED: 18 Apr 2004 (20040418/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> l3
L4 1 L3

=> d l4 ti fbib abs

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2004 ACS on STN
TI Phenoxyalkanoic acids as peroxisome proliferator activator receptor

(PPARα) agonists
AN 2002:637514 CAPLUS
DN 137:185319
TI Phenoxyalkanoic acids as peroxisome proliferator activator receptor (PPARα) agonists
IN Hayward, Cheryl Myers; Perry, David Austen
PA Pfizer Products Inc., USA
SO PCT Int. Appl., 147 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002064130	A1	20020822	WO 2002-IB43	20020109
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
				US 2001-269057PP	20010215
	EP 1372632	A1	20040102	EP 2002-740088	20020109
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
				US 2001-269057PP	20010215
				WO 2002-IB43 W	20020109
	BR 2002007227	A	20040210	BR 2002-7227	20020109
				US 2001-269057PP	20010215
				WO 2002-IB43 W	20020109
	US 2002169192	A1	20021114	US 2002-76318	20020214
				US 2001-269057PP	20010215

OS MARPAT 137:185319
AB 3-AWEN(CH2R3)12CR5R6C6H4BCR1R2Z [A = H, (un)substituted NH2, alkoxy, aryl, cycloalkyl, heterocyclic; W = bond, (un)substituted NH, azaalkylene, alkylene, cycloalkylene; E = CO, SO2; B = O, S, S(O), SO2, CH2, NH; Z = CO2H, CHO, CH2OH, alkoxycarbonyl, CN, CONHOH, tetrazolyl, tetrazolylaminocarbonyl, 4,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl, 3-oxoisoxazolidin-4-ylaminocarbonyl, CONHSO2R4; R1 = H, alkyl, cycloalkyl; R2 = H, cycloalkyl, (un)substituted alkyl; R3 = (un)substituted alkyl, alkenyl, alkynyl; R4 = (un)substituted alkyl, NH2; R5, R6 = H, alkyl, cycloalkyl, cycloalkylalkyl; CR5R6 = carbocyclic] were prepared for use as PPARα activators (no data). These compds. elevate certain plasma lipid levels, including HDL-cholesterol and lower certain plasma lipid levels, such as LDL-cholesterol and triglycerides and are used to treat diseases which are exacerbated by low levels of HDL-cholesterol and/or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases, in mammals, including humans. Thus, 3-MeOC6H4CH2CH2NH2 was demethylated, converted to the amide with heptanoic acid, and treated with Cl3CCMeEtOH to give 3-Me(CH2)5CONHCH2CH2C6H4OCMeEtCO2H which was converted to the benzyl ester and reduced to 3-Me(CH2)6NHCH2CH2C6H4OCMeEtCO2CH2Ph. This ester was treated with 2,4-F2C6H3NCO and debenzylated to give 3-Me(CH2)6N(CONHC6H3F2-2,4)CH2CH2C6H4OCMeEtCO2H.
RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> logoff hold
COST IN U.S. DOLLARS SINCE FILE TOTAL

	ENTRY	SESSION
FULL ESTIMATED COST	3.42	159.74

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-0.69	-0.69

SESSION WILL BE HELD FOR 60 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 07:22:34 ON 19 APR 2004

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1623PAZ

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	JAN 27	Source of Registration (SR) information in REGISTRY updated and searchable
NEWS	4	JAN 27	A new search aid, the Company Name Thesaurus, available in CA/CAplus
NEWS	5	FEB 05	German (DE) application and patent publication number format changes
NEWS	6	MAR 03	MEDLINE and LMEDLINE reloaded
NEWS	7	MAR 03	MEDLINE file segment of TOXCENTER reloaded
NEWS	8	MAR 03	FRANCEPAT now available on STN
NEWS	9	MAR 29	Pharmaceutical Substances (PS) now available on STN
NEWS	10	MAR 29	WPIFV now available on STN
NEWS	11	MAR 29	No connect hour charges in WPIFV until May 1, 2004
NEWS	12	MAR 29	New monthly current-awareness alert (SDI) frequency in RAPRA

NEWS EXPRESS	MARCH 31 CURRENT WINDOWS VERSION IS V7.00A, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 13 APRIL 2004
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 10:00:49 ON 19 APR 2004

```
=> logoff hold
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                         0.21       0.21

 SESSION WILL BE HELD FOR 60 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 10:00:57 ON 19 APR 2004

Connecting via Winsock to STN



Welcome to STN International!  Enter x:x

LOGINID:SSSPTA1623PAZ

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2


* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1           Web Page URLs for STN Seminar Schedule - N. America
 NEWS  2           "Ask CAS" for self-help around the clock
 NEWS  3  JAN 27   Source of Registration (SR) information in REGISTRY updated
                   and searchable
 NEWS  4  JAN 27   A new search aid, the Company Name Thesaurus, available in
                   CA/CAplus
 NEWS  5  FEB 05   German (DE) application and patent publication number format
                   changes
 NEWS  6  MAR 03   MEDLINE and LMEDLINE reloaded
 NEWS  7  MAR 03   MEDLINE file segment of TOXCENTER reloaded
 NEWS  8  MAR 03   FRANCEPAT now available on STN
 NEWS  9  MAR 29   Pharmaceutical Substances (PS) now available on STN
 NEWS 10  MAR 29   WPIFV now available on STN
 NEWS 11  MAR 29   No connect hour charges in WPIFV until May 1, 2004
 NEWS 12  MAR 29   New monthly current-awareness alert (SDI) frequency in RAPRA

 NEWS EXPRESS  MARCH 31 CURRENT WINDOWS VERSION IS V7.00A, CURRENT
               MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
               AND CURRENT DISCOVER FILE IS DATED 13 APRIL 2004
 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS INTER    General Internet Information
 NEWS LOGIN    Welcome Banner and News Items
 NEWS PHONE    Direct Dial and Telecommunication Network Access to STN
 NEWS WWW      CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

  * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 11:41:50 ON 19 APR 2004

=> file reg
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
```

	ENTRY	SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 11:42:02 ON 19 APR 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 18 APR 2004 HIGHEST RN 676118-37-9
DICTIONARY FILE UPDATES: 18 APR 2004 HIGHEST RN 676118-37-9

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2004

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
Uploading C:\Examination Auxillary files\10076318\10076318 try 2.str



chain nodes :
2 3 4 5 11 12 13 14 15 16 17 18 19
ring nodes :
1 6 7 8 9 10
chain bonds :
1-2 2-3 3-4 4-5 4-17 5-18 7-11 11-12 12-13 13-14 13-15 14-19 15-16
ring bonds :
1-6 1-10 6-7 7-8 8-9 9-10
exact/norm bonds :
1-2 2-3 12-13 13-14 13-15 14-19
exact bonds :
3-4 5-18 7-11 11-12 15-16
normalized bonds :
1-6 1-10 4-5 4-17 6-7 7-8 8-9 9-10

Match level :
1:Atom 2:CLASS 3:CLASS 4:CLASS 5:CLASS 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS
19:CLASS

```
L1      STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1                STR
```




```
Structure attributes must be viewed using STN Express query preparation.


=> search l1 sss sam
SAMPLE SEARCH INITIATED 11:44:02 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -      9 TO ITERATE

100.0% PROCESSED       9 ITERATIONS                                3 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:            9 TO      360
PROJECTED ANSWERS:               3 TO      163

L2            3 SEA SSS SAM L1

=> d scan

L2   3 ANSWERS   REGISTRY  COPYRIGHT 2004 ACS on STN
IN   Butanoic acid, 2-[3-[2-[[[(2,4-difluorophenyl)amino]carbonyl]heptylamino]e
     thyl]phenoxy]-2-methyl-, (2S)- (9CI)
MF   C27 H36 F2 N2 O4

Absolute stereochemistry.
```



HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):3

L2 3 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Butanoic acid, 2-[3-[2-[[[(3,5-dimethoxyphenyl)amino]carbonyl]heptylamino]ethyl]phenoxy]-2-methyl- (9CI)
MF C29 H42 N2 O6



L2 3 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Butanoic acid, 2-[3-[2-[[[(4-fluorophenyl)amino]carbonyl]heptylamino]ethyl]phenoxy]-2-methyl- (9CI)
MF C27 H37 F N2 O4



ALL ANSWERS HAVE BEEN SCANNED

=> search l1 sss full
FULL SEARCH INITIATED 11:44:57 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 292 TO ITERATE

100.0% PROCESSED 292 ITERATIONS 75 ANSWERS
SEARCH TIME: 00.00.01

L3 75 SEA SSS FUL L1

=> d scan

L3 75 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN

IN Butanoic acid, 2-[3-[2-[[[[2-(2,4-difluorophenyl)ethyl]amino]carbonyl]pentylamino]ethyl]phenoxy]-2-methyl- (9CI)
MF C27 H36 F2 N2 O4



HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):10

L3 75 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Butanoic acid, 2-[3-[2-[(2,4-dimethoxybenzoyl)heptylamino]ethyl]phenoxy]-2-methyl- (9CI)
MF C29 H41 N O6



L3 75 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Butanoic acid, 2-[3-[2-[heptyl[(4-hydroxyphenyl)acetyl]amino]ethyl]phenoxy]-2-methyl- (9CI)
MF C28 H39 N O5



L3 75 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Butanoic acid, 2-[3-[2-[[[(4-ethylphenyl)amino]carbonyl]heptylamino]ethyl]phenoxy]-2-methyl-, (2R)- (9CI)
MF C29 H42 N2 O4

Absolute stereochemistry.



L3 75 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Butanoic acid, 2-[3-[2-[[[(3,4-difluorophenyl)amino]carbonyl]heptylamino]ethyl]phenoxy]-2-methyl- (9CI)
MF C27 H36 F2 N2 O4



L3 75 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Butanoic acid, 2-[3-[2-[[[(2,4-difluorophenyl)amino]carbonyl]heptylamino]ethyl]phenoxy]-2-methyl-, (2R)- (9CI)
MF C27 H36 F2 N2 O4

Absolute stereochemistry.



L3 75 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Butanoic acid, 2-[3-[2-[heptyl(1H-indol-3-ylacetyl)amino]ethyl]phenoxy]-2-methyl- (9CI)
MF C30 H40 N2 O4



L3 75 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Butanoic acid, 2-[3-[2-[[2-(2,4-difluorophenyl)ethyl](1-oxo-3-phenylpropyl)amino]ethyl]phenoxy]-2-methyl- (9CI)
MF C30 H33 F2 N O4



L3 75 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Butanoic acid, 2-[3-[2-[[2-(2,4-difluorophenyl)ethyl][(pentylamino)carbonyl]amino]ethyl]phenoxy]-2-methyl-, (2S)- (9CI)
MF C27 H36 F2 N2 O4

Absolute stereochemistry.



L3 75 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Butanoic acid, 2-[3-[2-[heptyl[[[4-(trifluoromethoxy)phenyl]amino]carbonyl]amino]ethyl]phenoxy]-2-methyl- (9CI)
MF C28 H37 F3 N2 O5



L3 75 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Acetic acid, [3-[2-[[[(2,4-dimethoxyphenyl)amino]carbonyl]heptylamino]ethy

l]phenoxy]- (9CI)
MF C26 H36 N2 O6



HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):10

L3 75 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Butanoic acid, 2-[3-[2-[(benzo[b]thien-3-ylacetyl)heptylamino]ethyl]phenoxy]-2-methyl- (9CI)
MF C30 H39 N O4 S



L3 75 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Butanoic acid, 2-methyl-2-[3-[2-[(1-oxoheptyl)[2-(3-pyridinyl)ethyl]amino]ethyl]phenoxy]- (9CI)
MF C27 H38 N2 O4



L3 75 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Butanoic acid, 2-[3-[2-[heptyl[[[4-(1-methylethyl)phenyl]amino]carbonyl]amino]ethyl]phenoxy]-2-methyl- (9CI)
MF C30 H44 N2 O4



L3 75 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Butanoic acid, 2-[3-[2-[[[[2-(2,4-difluorophenyl)ethyl]amino]carbonyl]hexy

lamino]ethyl]phenoxy]-2-methyl- (9CI)
MF C28 H38 F2 N2 O4



L3 75 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Butanoic acid, 2-[3-[2-[[(4-fluorophenyl)acetyl]heptylamino]ethyl]phenoxy]-2-methyl- (9CI)
MF C28 H38 F N O4



L3 75 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Butanoic acid, 2-[3-[2-[[(2,4-difluorophenyl)acetyl]heptylamino]ethyl]phenoxy]-2-methyl- (9CI)
MF C28 H37 F2 N O4



L3 75 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Butanoic acid, 2-[3-[2-[heptyl[(4-hydroxyphenyl)acetyl]amino]ethyl]phenoxy]-2-methyl-, (2S)- (9CI)
MF C28 H39 N O5

Absolute stereochemistry.



L3 75 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Butanoic acid, 2-[3-[2-[[[(4-fluorophenyl)amino]carbonyl]heptylamino]ethyl]phenoxy]-2-methyl- (9CI)
MF C27 H37 F N2 O4



L3 75 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Propanoic acid, 2-[3-[2-[[[(2,4-dimethoxyphenyl)amino]carbonyl]heptylamino]ethyl]phenoxy]-2-methyl- (9CI)
MF C28 H40 N2 O6



L3 75 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Butanoic acid, 2-[3-[2-[heptyl[(3-methoxyphenyl)acetyl]amino]ethyl]phenoxy]-2-methyl- (9CI)
MF C29 H41 N O5



HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):\0
'\0' IS NOT VALID HERE

To display more answers, enter the number of answers you would like to see. To end the display, enter "NONE", "N", "0", or "END".
HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):end

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	157.94	158.15

FILE 'CAPLUS' ENTERED AT 11:45:58 ON 19 APR 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 19 Apr 2004 VOL 140 ISS 17
FILE LAST UPDATED: 18 Apr 2004 (20040418/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> l3
L4 1 L3

=> d l4 ti fbib abs

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2004 ACS on STN
TI Phenoxyalkanoic acids as peroxisome proliferator activator receptor (PPARα) agonists
AN 2002:637514 CAPLUS
DN 137:185319
TI Phenoxyalkanoic acids as peroxisome proliferator activator receptor (PPARα) agonists
IN Hayward, Cheryl Myers; Perry, David Austen
PA Pfizer Products Inc., USA
SO PCT Int. Appl., 147 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002064130	A1	20020822	WO 2002-IB43	20020109

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

```
                                                US 2001-269057PP 20010215
     EP 1372632        A1   20040102          EP 2002-740088   20020109
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
                                                US 2001-269057PP 20010215
                                                WO 2002-IB43   W 20020109
     BR 2002007227     A    20040210          BR 2002-7227     20020109
                                                US 2001-269057PP 20010215
                                                WO 2002-IB43   W 20020109
     US 2002169192     A1   20021114          US 2002-76318    20020214
                                                US 2001-269057PP 20010215
OS   MARPAT 137:185319
AB   3-AWEN(CH2R3)12CR5R6C6H4BCR1R2Z [A = H, (un)substituted NH2, alkoxy, aryl,
     cycloalkyl, heterocyclic; W = bond, (un)substituted NH, azaalkylene,
     alkylene, cycloalkylene; E = CO, SO2; B = O, S, S(O), SO2, CH2, NH; Z =
     CO2H, CHO, CH2OH, alkoxycarbonyl, CN, CONHOH, tetrazolyl,
     tetrazolylaminocarbonyl, 4,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl,
     3-oxoisoxazolidin-4-ylaminocarbonyl, CONHSO2R4; R1 = H, alkyl, cycloalkyl;
     R2 = H, cycloalkyl, (un)substituted alkyl; R3 = (un)substituted alkyl,
     alkenyl, alkynyl; R4 = (un)substituted alkyl, NH2; R5, R6 = H, alkyl,
     cycloalkyl, cycloalkylalkyl; CR5R6 = carbocyclic] were prepared for use as
     PPARα activators (no data).  These compds. elevate certain plasma
     lipid levels, including HDL-cholesterol and lower certain plasma lipid
     levels, such as LDL-cholesterol and triglycerides and are used to treat
     diseases which are exacerbated by low levels of HDL-cholesterol and/or
     high levels of LDL-cholesterol and triglycerides, such as atherosclerosis
     and cardiovascular diseases, in mammals, including humans.  Thus,
     3-MeOC6H4CH2CH2NH2 was demethylated, converted to the amide with heptanoic
     acid, and treated with Cl3CCMeEtOH to give 3-Me(CH2)5CONHCH2CH2C6H4OCMeEtC
     O2H which was converted to the benzyl ester and reduced to
     3-Me(CH2)6NHCH2CH2C6H4OCMeEtCO2CH2Ph.  This ester was treated with
     2,4-F2C6H3NCO and debenzylated to give 3-Me(CH2)6N(CONHC6H3F2-
     2,4)CH2CH2C6H4OCMeEtCO2H.
RE.CNT  6     THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT


=> lgoff hold
             0 LGOFF
         31518 HOLD
         22293 HOLDS
         53022 HOLD
                 (HOLD OR HOLDS)
L5           0 LGOFF HOLD
                 (LGOFF(W)HOLD)

=> logoff hold
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                      ENTRY     SESSION
FULL ESTIMATED COST                                     7.05      165.20

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                      ENTRY     SESSION
CA SUBSCRIBER PRICE                                    -0.69       -0.69

 SESSION WILL BE HELD FOR 60 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 11:46:59 ON 19 APR 2004

Connecting via Winsock to STN
```

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1623PAZ

PASSWORD:
* * * * * * RECONNECTED TO STN INTERNATIONAL * * * * * *
SESSION RESUMED IN FILE 'CAPLUS' AT 11:52:56 ON 19 APR 2004
FILE 'CAPLUS' ENTERED AT 11:52:56 ON 19 APR 2004
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	7.05	165.20

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-0.69	-0.69

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	7.05	165.20

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-0.69	-0.69

FILE 'REGISTRY' ENTERED AT 11:53:08 ON 19 APR 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 18 APR 2004 HIGHEST RN 676118-37-9
DICTIONARY FILE UPDATES: 18 APR 2004 HIGHEST RN 676118-37-9

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2004

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
Uploading C:\Examination Auxillary files\10076318\10076318 try 2 obv.str





chain nodes :
2 3 4 5 11 12 13 14 15 16 17 18 19
ring nodes :
1 6 7 8 9 10
chain bonds :
1-2 2-3 3-4 4-5 4-17 5-18 11-12 12-13 13-14 13-15 14-19 15-16
ring bonds :
1-6 1-10 6-7 7-8 8-9 9-10
exact/norm bonds :
1-2 2-3 12-13 13-14 13-15 14-19
exact bonds :
3-4 5-18 11-12 15-16
normalized bonds :
1-6 1-10 4-5 4-17 6-7 7-8 8-9 9-10

Match level :
1:Atom 2:CLASS 3:CLASS 4:CLASS 5:CLASS 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS
19:CLASS 20:CLASS

L6 STRUCTURE UPLOADED

=> d l6
L6 HAS NO ANSWERS
L6 STR



Structure attributes must be viewed using STN Express query preparation.

=> search l6 sss sam
SAMPLE SEARCH INITIATED 11:54:02 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 171 TO ITERATE

100.0% PROCESSED 171 ITERATIONS 7 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 2636 TO 4204
PROJECTED ANSWERS: 7 TO 298

L7 7 SEA SSS SAM L6

=> d scan

L7 7 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN Propanoic acid, 2-[4-[2-[heptyl[[(2,4,6-trimethylphenyl)amino]carbonyl]amino]ethyl]phenoxy]-2-methyl- (9CI)
MF C29 H42 N2 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> search l6 sss full
FULL SEARCH INITIATED 11:54:45 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 3488 TO ITERATE

100.0% PROCESSED 3488 ITERATIONS 111 ANSWERS
SEARCH TIME: 00.00.01

L8 111 SEA SSS FUL L6

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	156.26	321.46

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-0.69

FILE 'CAPLUS' ENTERED AT 11:54:56 ON 19 APR 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 19 Apr 2004 VOL 140 ISS 17
FILE LAST UPDATED: 18 Apr 2004 (20040418/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> l8
L9 31 L8

=> d l9 21-31 ti

L9 ANSWER 21 OF 31 CAPLUS COPYRIGHT 2004 ACS on STN
TI Pharmaceutical compositions containing ACAT and MMP inhibitors for the treatment of atherosclerotic lesions

L9 ANSWER 22 OF 31 CAPLUS COPYRIGHT 2004 ACS on STN
TI A Ureido-Thioisobutyric Acid (GW9578) Is a Subtype-Selective PPARα Agonist with Potent Lipid-Lowering Activity

L9 ANSWER 23 OF 31 CAPLUS COPYRIGHT 2004 ACS on STN
TI Direct tritium labeling of multifunctional compounds using organoiridium catalysis. 2

L9 ANSWER 24 OF 31 CAPLUS COPYRIGHT 2004 ACS on STN

TI Identification of peroxisome proliferator-activated receptor ligands from a biased chemical library

L9 ANSWER 25 OF 31 CAPLUS COPYRIGHT 2004 ACS on STN
TI Generation of secondary alkyl amines on solid support by borane reduction. Applications to the parallel synthesis of PPAR ligands. [Erratum to document cited in CA127:220440]

L9 ANSWER 26 OF 31 CAPLUS COPYRIGHT 2004 ACS on STN
TI Prevention or treatment of type 2 diabetes or cardiovascular disease with PPAR modulators

L9 ANSWER 27 OF 31 CAPLUS COPYRIGHT 2004 ACS on STN
TI Use of agonists of the peroxisome proliferator activated receptor α for treating obesity

L9 ANSWER 28 OF 31 CAPLUS COPYRIGHT 2004 ACS on STN
TI Generation of secondary alkyl amines on solid support by borane reduction. Application to the parallel synthesis of PPAR ligands

L9 ANSWER 29 OF 31 CAPLUS COPYRIGHT 2004 ACS on STN
TI Potent hypocholesterolemic activity of novel ureido phenoxyisobutyrates correlates with their intrinsic fibrate potency and not with their ACAT inhibitory activity

L9 ANSWER 30 OF 31 CAPLUS COPYRIGHT 2004 ACS on STN
TI Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors α and γ

L9 ANSWER 31 OF 31 CAPLUS COPYRIGHT 2004 ACS on STN
TI Preparation of antiatherosclerotic diaryl ureas

=> d l9 21-31 ti fbib abs

L9 ANSWER 21 OF 31 CAPLUS COPYRIGHT 2004 ACS on STN
TI Pharmaceutical compositions containing ACAT and MMP inhibitors for the treatment of atherosclerotic lesions
AN 2000:84604 CAPLUS
DN 132:141951
TI Pharmaceutical compositions containing ACAT and MMP inhibitors for the treatment of atherosclerotic lesions
IN Bocan, Thomas Michael Andrew
PA Warner-Lambert Company, USA
SO PCT Int. Appl., 222 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000004892	A2	20000203	WO 1999-US13948	19990618
	WO 2000004892	A3	20000518		
	W: AE, AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
				US 1998-93639P P	19980721
	CA 2335062	AA	20000203	CA 1999-2335062	19990618

				US 1998-93639P P 19980721
				WO 1999-US13948W 19990618
AU 9947017		A1	20000214	AU 1999-47017 19990618
				US 1998-93639P P 19980721
				WO 1999-US13948W 19990618
BR 9912296		A	20010417	BR 1999-12296 19990618
				US 1998-93639P P 19980721
				WO 1999-US13948W 19990618
EP 1098662		A2	20010516	EP 1999-930483 19990618
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
				US 1998-93639P P 19980721
				WO 1999-US13948W 19990618
EE 200100046		A	20020617	EE 2001-46 19990618
				US 1998-93639P P 19980721
				WO 1999-US13948W 19990618
JP 2002521328		T2	20020716	JP 2000-560885 19990618
				US 1998-93639P P 19980721
				WO 1999-US13948W 19990618
ZA 2001000294		A	20020110	ZA 2001-294 20010110
				US 1998-93639P P 19980721
BG 105162		A	20011231	BG 2001-105162 20010117
				US 1998-93639P P 19980721
				WO 1999-US13948W 19990618
NO 2001000291		A	20010118	NO 2001-291 20010118
				US 1998-93639P P 19980721
				WO 1999-US13948W 19990618
HR 2001000055		A1	20020430	HR 2001-55 20010119
				US 1998-93639P P 19980721
				WO 1999-US13948W 19990618

AB Acyl-CoA:cholesterol acyltransferase (ACAT) and matrix metalloproteinase (MMP) inhibitors are coadministered for the reduction of both the macrophage and smooth muscle cell component of atherosclerotic lesions, thus impairing the expansion of existing lesions and the development of new lesions and for the prevention of plaque rupture and the promotion of lesion regression in a mammal. The direct antiatherosclerotic potential of the combination of ACAT inhibitor, [[2,4,6-tris-(1-methyl)phenyl]acetyl]-2,6-bis(1-methylethyl)phenyl sulfamic acid, and the HMG-CoA reductase inhibitor, simavastatin, in rabbits was studied. A tablet contained 2-(4'-bromobiphenyl-4-sulfonylamino)-3-Me butyric acid 25 ACAT compound lactose 50, corn starch 20, and magnesium stearate 5 mg.

L9 ANSWER 22 OF 31 CAPLUS COPYRIGHT 2004 ACS on STN
TI A Ureido-Thioisobutyric Acid (GW9578) Is a Subtype-Selective PPARα Agonist with Potent Lipid-Lowering Activity
AN 1999:567006 CAPLUS
DN 131:306978
TI A Ureido-Thioisobutyric Acid (GW9578) Is a Subtype-Selective PPARα Agonist with Potent Lipid-Lowering Activity
AU Brown, Peter J.; Winegar, Deborah A.; Plunket, Kelli D.; Moore, Linda B.; Lewis, Michael C.; Wilson, Joan G.; Sundseth, Scott S.; Koble, Cecilia S.; Wu, Zhengdong; Chapman, James M.; Lehmann, Juergen M.; Kliewer, Steven A.; Willson, Timothy M.
CS Departments of Medicinal Chemistry Metabolic Diseases and Molecular Endocrinology, Glaxo Wellcome Research & Development, Research Triangle Park, NC, 27709, USA
SO Journal of Medicinal Chemistry (1999), 42(19), 3785-3788
CODEN: JMCMAR; ISSN: 0022-2623
PB American Chemical Society
DT Journal
LA English
AB Several fibrates and ureido-fibrates were compared for their agonist activity at the PPARα (peroxisome proliferator-activated

receptor-α). The ureido-fibrates were potent agonists at murine PPARα:, however, like the fibrates, they showed only moderate levels of subtype selectivity. The ureido-thioisobutyric acid derivative (GW9578) was prepared and shown to be a selective PPARα agonist. The lipid-lowering activity of the fibrates and GW9578 were determined: GW9578 had good activity. The lipid-lowering activity of the fibrates was correlated with their lipid-lowering activity. GW9578 decreased total LDL cholesterol and apoC-III levels, indicating that its mechanism was clin. relevant.

RE.CNT 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 23 OF 31 CAPLUS COPYRIGHT 2004 ACS on STN
TI Direct tritium labeling of multifunctional compounds using organoiridium catalysis. 2
AN 1999:525826 CAPLUS
DN 131:299124
TI Direct tritium labeling of multifunctional compounds using organoiridium catalysis. 2
AU Shu, A. Y. L.; Saunders, D.; Levinson, S. H.; Landvatter, S. W.; Mahoney, A.; Senderoff, S. G.; Mack, J. F.; Heys, J. R.
CS Radiochemistry, SmithKline Beecham Pharmaceuticals, King of Prussia, PA, 19406, USA
SO Journal of Labelled Compounds & Radiopharmaceuticals (1999), 42(8), 797-807
CODEN: JLCRD4; ISSN: 0362-4803
PB John Wiley & Sons Ltd.
DT Journal
LA English
AB A variety of complex compds. were labeled with tritium gas by catalytic exchange in the presence of catalyst precursors [(cod)Ir(dppe)]BF4 or [(cod)Ir(py)(PCy3)]BF4. In most cases, predictable regioselectivity and high specific activities are achieved. These results are compared in some cases to the results of labeling related compds. with [(cod)Ir(PPh3)2]BF4. Preredn. of the catalyst precursors in situ with hydrogen allows the use of smaller quantities of tritium gas and reduces the amount of radioactive waste. Two or more compds. can be labeled simultaneously as mixts. then separated in the HPLC purification step to increase compound throughput.
RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 24 OF 31 CAPLUS COPYRIGHT 2004 ACS on STN
TI Identification of peroxisome proliferator-activated receptor ligands from a biased chemical library
AN 1999:474434 CAPLUS
Correction of: 1998:80482
DN 131:97348
Correction of: 128:215212
TI Identification of peroxisome proliferator-activated receptor ligands from a biased chemical library
AU Brown, Peter J.; Smith-Oliver, Tracey A.; Charifson, Paul S.; Tomkinson, Nicholas C. O.; Fivush, Adam M.; Sternbach, Daniel D.; Wade, Laura E.; Orband-Miller, Lisa; Parks, Derek J.; Blanchard, Steven G.
CS Dep. Medicinal Chem., Wellcome Research & Development, Research Triangle, NC, 27709-3398, USA
SO Chemistry & Biology (1997), 4(12), 909-918
CODEN: CBOLE2; ISSN: 1074-5521
PB Current Biology Ltd.
DT Journal
LA English
AB Background: The peroxisome proliferator-activated receptors (PPARs) were cloned as orphan members of the nuclear receptor superfamily of transcription factors. The identification of subtype-selective ligands

for PPARα and PPARγ has led to the discovery of their roles in the regulation of lipid metabolism and glucose homeostasis. No subtype-selective PPARδ ligands are available and the function of this subtype is currently unknown. Results: A three-component library was designed in which one of the monomers was biased towards the PPARs and the other two monomers were chosen to add chemical diversity. Synthesis and screening of the library resulted in the identification of pools with activity on each of the PPAR subtypes. Deconvolution of the pools with the highest activity on PPARδ led to the identification of GW 2433 as the first high-affinity PPARδ ligand. [3H]GW 2433 is an effective radioligand for use in PPARδ competition-binding assays. Conclusions: The synthesis of biased chemical libraries is an efficient approach to the identification of lead mols. for members of sequence-related receptor families. This approach is well suited to the discovery of small-mol. ligands for orphan receptors.

L9 ANSWER 25 OF 31 CAPLUS COPYRIGHT 2004 ACS on STN
TI Generation of secondary alkyl amines on solid support by borane reduction. Applications to the parallel synthesis of PPAR ligands. [Erratum to document cited in CA127:220440]
AN 1999:157196 CAPLUS
DN 130:267199
TI Generation of secondary alkyl amines on solid support by borane reduction. Applications to the parallel synthesis of PPAR ligands. [Erratum to document cited in CA127:220440]
AU Brown, Peter J.; Hurley, Kevin P.; Stuart, L. William; Wilson, Timothy M.
CS Department Medicinal Chemistry, Glaxo Wellcome Research Development, Research Traiangle Park, NC, 27709, USA
SO Synthesis (1999), (2), 364
CODEN: SYNTBF; ISSN: 0039-7881
PB Georg Thieme Verlag
DT Journal
LA English
AB On page 780, column 2, line 7, the abbreviation DIC should read as diisopropylcarbodiimide.

L9 ANSWER 26 OF 31 CAPLUS COPYRIGHT 2004 ACS on STN
TI Prevention or treatment of type 2 diabetes or cardiovascular disease with PPAR modulators
AN 1998:112233 CAPLUS
DN 128:176165
TI Prevention or treatment of type 2 diabetes or cardiovascular disease with PPAR modulators
IN Paterniti, James R.; Briggs, Michael R.; Mukherjee, Ranjan; Auwerx, Johan; Stael, Bart
PA Ligand Pharmaceuticals Inc., USA
SO PCT Int. Appl., 62 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9805331	A2	19980212	WO 1997-US13605	19970801
	WO 9805331	A3	19980507		

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG

				US 1996-22949P P 19960802
	AU 9740507	A1	19980225	AU 1997-40507 19970801
				US 1996-22949P P 19960802
				WO 1997-US13605W 19970801
	EP 930882	A2	19990728	EP 1997-938101 19970801
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, NL, SE, PT, IE, FI			
				US 1996-22949P P 19960802
				WO 1997-US13605W 19970801

AB This invention relates to methods and compns. for the prevention and treatment of Type 2 diabetes and cardiovascular disease with diabetic or pre-diabetic conditions or symptoms associated therewith using both a PPARγ (Peroxisome proliferator activated receptor) agonist and a PPARα agonist or a compound which activates both PPARγ and PPARα. A preferred PPARγ agonist is a thiazolidinedione compound, including BRL 49653, troglitazone, pioglitazone, ciglitazone, WAY-120,744, englitazone, AD 5075, darglitazone, and congeners, analogs, derivs. and pharmaceutically acceptable salts thereof. A preferred PPARα agonist is a fibrate compound including gemifbrozil, fenfibrate, bezofibrate, clofibrate, ciprofibrate, and analogs, derivs. and pharmaceutically acceptable salts thereof. An example is given showing that a PPARγ agonist and a PPARα agonist in combination achieved enhanced antidiabetic and cardioprotective effects over either agent alone.

L9 ANSWER 27 OF 31 CAPLUS COPYRIGHT 2004 ACS on STN
TI Use of agonists of the peroxisome proliferator activated receptor α for treating obesity
AN 1997:672266 CAPLUS
DN 127:326560
TI Use of agonists of the peroxisome proliferator activated receptor α for treating obesity
IN Willson, Timothy Mark
PA Glaxo Group Ltd., UK; Willson, Timothy Mark
SO PCT Int. Appl., 21 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9736579	A1	19971009	WO 1997-EP1552	19970327
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
				GB 1996-6805 A	19960330
	AU 9725061	A1	19971022	AU 1997-25061	19970327
				GB 1996-6805 A	19960330
				WO 1997-EP1552 W	19970327
	ZA 9702685	A	19971120	ZA 1997-2685	19970327
				GB 1996-6805 A	19960330
	US 6028109	A	20000222	US 1998-155321	19980928
				GB 1996-6805 A	19960330
				WO 1997-EP1552 W	19970327

AB The invention discloses the use of agonists of the peroxisome proliferator activated receptor α (PPARα) for the manufacture of a medicament for the treatment of obesity, as well as methods of treating obesity comprising the administration of a therapeutic amount of a PPARα agonist. Preparation of 2-[4-(2-(3-(4-fluorophenyl)-1-

heptylureido)ethyl)phenoxy]-2-methylpropionic acid is described, as are preparation of the corresponding tritiated radioligand, binding data, and weight loss data.

L9 ANSWER 28 OF 31 CAPLUS COPYRIGHT 2004 ACS on STN
TI Generation of secondary alkyl amines on solid support by borane reduction. Application to the parallel synthesis of PPAR ligands
AN 1997:505482 CAPLUS
DN 127:220440
TI Generation of secondary alkyl amines on solid support by borane reduction. Application to the parallel synthesis of PPAR ligands
AU Brown, Peter J.; Hurley, Kevin P.; Stuart, L. William; Willson, Timothy M.
CS Department Medicinal Chemistry, Glaxo Wellcome Research Development, Research Triangle Park, NC, 27709, USA
SO Synthesis (1997), (7), 778-782
CODEN: SYNTBF; ISSN: 0039-7881
PB Thieme
DT Journal
LA English
OS CASREACT 127:220440
AB A solid-phase parallel synthesis of fibrate peroxisome proliferator-activated receptor (PPAR) ligands, 4-(HO2CCMe2O)C6H4(CH2)2NRCONHR1 [R = heptyl, Ph(CH2)2, PhOCHMeCH2, 3,5-(CF3)2C6H3CH2; R1 = 4-FC6H4, 2,4-(MeO)2C6H3, 4-AcC6H4, 2,3-Cl2C6H3] was developed. The key reaction is a novel borane reduction of resin bound amides that generates secondary amines not accessible by reductive alkylation of primary amines. 4-(HO2CCMe2O)C6H4(CH2)2NHfmoc (fmoc = 9-fluorenylmethoxycarbonyl) was loaded onto Sasrin resin via the carboxylic acid. The amine was elaborated by amide bond formation followed by reduction with borane. The resulting secondary amines reacted with aryl isocyanates to generate the fibrates in high yield and purity following cleavage from the solid support.

L9 ANSWER 29 OF 31 CAPLUS COPYRIGHT 2004 ACS on STN
TI Potent hypocholesterolemic activity of novel ureido phenoxyisobutyrates correlates with their intrinsic fibrate potency and not with their ACAT inhibitory activity
AN 1997:428048 CAPLUS
DN 127:144748
TI Potent hypocholesterolemic activity of novel ureido phenoxyisobutyrates correlates with their intrinsic fibrate potency and not with their ACAT inhibitory activity
AU Hawke, Roy L.; Chapman, James M.; Winegar, Deborah A.; Salisbury, Jo A.; Welch, Richard M.; Brown, Alan; Franzmann, Karl W.; Sigel, Carl
CS Division of Pharmacokinetics and Drug Metabolism, Wellcome Research Laboratories, Research Triangle Park, NC, 27709, USA
SO Journal of Lipid Research (1997), 38(6), 1189-1203
CODEN: JLPRAW; ISSN: 0022-2275
PB Lipid Research, Inc.
DT Journal
LA English
AB The hypocholesterolemic activity for novel ureido fibrate analogs was over 100-fold greater than for any "second-generation" fibrate in cholesterol-fed rats. A comparison of 12 related analogs revealed that the optimal configuration for a urea-bridging region located between two aromatic rings consisted of a trisubstituted nitrogen, optimally substituted with a C7 alkyl chain and linked by dimethylene to a phenoxyisobutyrate moiety found in most fibrate analogs. The hypocholesterolemic potency of these compds. was found to correlate with their increased intrinsic fibrate activity as determined by the ability to induce ω-hydroxylase activity either in rat hepatocyte cultures or in vivo, and not with their 10-fold increased ACAT inhibitory potency when compared to other fibrates.

The most active compound, 2-(4-(2-(N'-(2,4-difluorophenyl)-N-heptylureido)ethyl)phenoxy)-2-methylpropionic acid (I) was found to induce ω-hydroxylase activity in hepatocytes in concns. between 5 and 100 nM compared to 1-20 μM concns. for bezafibrate, and lower serum VLDL + LDL cholesterol in rats at doses between 0.1 and 0.5 mg/kg per day compared to doses of 25-100 mg/kg per day for bezafibrate. Single-dose pharmacokinetic studies with I indicated that total drug exposure will be much lower at hypocholesterolemic doses due to the enhanced intrinsic activity, and may result in an improved safety profile for these novel trisubstituted ureido fibrate analogs in rats and humans compared to other fibrates.

L9 ANSWER 30 OF 31 CAPLUS COPYRIGHT 2004 ACS on STN
TI Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors α and γ
AN 1997:308252 CAPLUS
DN 127:30658
TI Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors α and γ
AU Kliewer, Steven A.; Sundseth, Scott S.; Jones, Stacey A.; Brown, Peter J.; Wisely, G. Bruce; Koble, Cecilia; Devchand, Pallavi; Wahli, Walter; Willson, Timothy M.; Lenhard, James M.; Lehmann, Jurgen M.
CS Departments of Molecular Endorinology, Metabolic Diseases, Medicinal Chemistry and Structural Chemistry, Glaxo Wellcome Research and Development, Research Triangle Park, NC, 27709, USA
SO Proceedings of the National Academy of Sciences of the United States of America (1997), 94(9), 4318-4323
CODEN: PNASA6; ISSN: 0027-8424
PB National Academy of Sciences
DT Journal
LA English
AB Peroxisome proliferator-activated receptors (PPARs) α and γ are key regulators of lipid homeostasis and are activated by a structurally diverse group of compds. including fatty acids, eicosanoids, and hypolipidemic drugs such as fibrates and thiazolidinediones. While thiazolidinediones and 15-deoxy-Δ12,14-prostaglandin J2 have been shown to bind to PPARγ, it has remained unclear whether other activators mediate their effects through direct interactions with the PPARs or via indirect mechanisms. Here, a novel fibrate designed GW2231 is described, that is a high-affinity ligand for both PPARα and PPARγ. Using GW2331 as a radioligand in competition binding assays, it is shown that certain mono- and polyunsatd. fatty acids bind directly to PPARα and PPARγ at physiol. concns., and that the eicosanoids 8(S)-hydroxyeicosatetraenoic acid and 15-deoxy-Δ12,14-prostaglandin J2 can function as subtype-selective ligands for PPARα and PPARγ, resp. These data provide evidence that PPARs serve as physiol. sensors of lipid levels and suggest a mol. mechanism whereby dietary fatty acids can modulate lipid homeostasis.

L9 ANSWER 31 OF 31 CAPLUS COPYRIGHT 2004 ACS on STN
TI Preparation of antiatherosclerotic diaryl ureas
AN 1992:612163 CAPLUS
DN 117:212163
TI Preparation of antiatherosclerotic diaryl ureas
IN Franzmann, Karl Witold; O'Connor, Kevin Julian; Hawke, Roy Lee; Chapman, James Mood
PA Wellcome Foundation Ltd., UK; University of South Carolina
SO PCT Int. Appl., 42 pp.
CODEN: PIXXD2
DT Patent
LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9210468	A1	19920625	WO 1991-GB2195	19911211
	W: AU, CA, HU, JP, KR, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, MC, NL, SE				
				GB 1990-27023	A 19901212
	CA 2098122	AA	19920613	CA 1991-2098122	19911211
				GB 1990-27023	A 19901212
	AU 9190560	A1	19920708	AU 1991-90560	19911211
	AU 647859	B2	19940331		
				GB 1990-27023	A 19901212
				WO 1991-GB2195	A 19911211
	ZA 9109773	A	19930611	ZA 1991-9773	19911211
				GB 1990-27023	A 19901212
	HU 64514	A2	19940128	HU 1993-1709	19911211
				GB 1990-27023	A 19901212
	JP 06507151	T2	19940811	JP 1991-501716	19911211
	JP 2951402	B2	19990920		
				GB 1990-27023	A 19901212
				WO 1991-GB2195	W 19911211
	EP 639178	A1	19950222	EP 1992-900716	19911211
	EP 639178	B1	19970903		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, MC, NL, SE				
				GB 1990-27023	A 19901212
				WO 1991-GB2195	W 19911211
	IL 100331	A1	19960912	IL 1991-100331	19911211
				GB 1990-27023	A 19901212
	AT 157651	E	19970915	AT 1992-900716	19911211
				GB 1990-27023	A 19901212
	US 5658944	A	19970819	US 1995-421997	19950414
				GB 1990-27023	A 19901212
				US 1991-805236	B119911211
				US 1992-962068	B319921016

OS MARPAT 117:212163

GI



I

AB Title compds. I (Ar = (substituted) mono- or bicyclic aromatic group containing 1 or 2 heteroatoms; D = H2C, HN, O; E = N, CH, G = H, (substituted) C1-12 alkyl, -C1-12 aralkyl; I = bond, C1-6 alkylene; n = 0-10; R, R1 = H, (substituted) C1-8 alkyl, -C1-8 alkanoyl, NC, carboxyalkoxy, etc.; K = HOCH2, HCO, H2NCOCH2NHCO, R2O2C, wherein R2 = H, C1-8 alkyl, aryl heteroaryl, aralkyl, heteroalkyl, etc.) and salts thereof, are prepared Carbobenzyloxytyramine (preparation given) was converted in 5 steps to I [Ar = 2,4-(MeO)2C6H3, D = NH, E = N, G = 1-heptyl, I = CH2, n = 0, R = R1 = Me, K = HO2C] (II). II inhibited CoA: cholesterol acyl transferase with IC50 = 4.5 μM. Pharmaceutical formulations comprising I are given.

=> d his

(FILE 'HOME' ENTERED AT 11:41:50 ON 19 APR 2004)

FILE 'REGISTRY' ENTERED AT 11:42:02 ON 19 APR 2004

L1 STRUCTURE UPLOADED

```
L2             3 SEARCH L1 SSS SAM
L3            75 SEARCH L1 SSS FULL

     FILE 'CAPLUS' ENTERED AT 11:45:58 ON 19 APR 2004
L4             1 L3
L5             0 LGOFF HOLD

     FILE 'REGISTRY' ENTERED AT 11:53:08 ON 19 APR 2004
L6               STRUCTURE UPLOADED
L7             7 SEARCH L6 SSS SAM
L8           111 SEARCH L6 SSS FULL

     FILE 'CAPLUS' ENTERED AT 11:54:56 ON 19 APR 2004
L9            31 L8

=> save temp l9  diabetcmpds/a
ANSWER SET L9 HAS BEEN SAVED AS 'DIABETCMPDS/A'

=> logoff hold
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                    52.44     373.90

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                    -7.62      -8.31

 SESSION WILL BE HELD FOR 60 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 12:23:51 ON 19 APR 2004

Connecting via Winsock to STN



Welcome to STN International!  Enter x:x

LOGINID:SSSPTA1623PAZ

PASSWORD:
 * * * * * * RECONNECTED TO STN INTERNATIONAL * * * * * *
SESSION RESUMED IN FILE 'CAPLUS' AT 13:17:19 ON 19 APR 2004
FILE 'CAPLUS' ENTERED AT 13:17:19 ON 19 APR 2004
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                    52.44     373.90

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                    -7.62      -8.31

=> logoff hold
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                    52.88     374.34

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                    -7.62      -8.31

 SESSION WILL BE HELD FOR 60 MINUTES
```

```
STN INTERNATIONAL SESSION SUSPENDED AT 13:17:50 ON 19 APR 2004

Connecting via Winsock to STN



Welcome to STN International!  Enter x:x

LOGINID:SSSPTA1623PAZ

PASSWORD:
 * * * * * * RECONNECTED TO STN INTERNATIONAL * * * * * *
SESSION RESUMED IN FILE 'CAPLUS' AT 13:47:53 ON 19 APR 2004
FILE 'CAPLUS' ENTERED AT 13:47:53 ON 19 APR 2004
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                      ENTRY    SESSION
FULL ESTIMATED COST                                   52.88     374.34

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                      ENTRY    SESSION
CA SUBSCRIBER PRICE                                   -7.62      -8.31

=> d his

     (FILE 'HOME' ENTERED AT 11:41:50 ON 19 APR 2004)

     FILE 'REGISTRY' ENTERED AT 11:42:02 ON 19 APR 2004
L1             STRUCTURE UPLOADED
L2           3 SEARCH L1 SSS SAM
L3          75 SEARCH L1 SSS FULL

     FILE 'CAPLUS' ENTERED AT 11:45:58 ON 19 APR 2004
L4           1 L3
L5           0 LGOFF HOLD

     FILE 'REGISTRY' ENTERED AT 11:53:08 ON 19 APR 2004
L6             STRUCTURE UPLOADED
L7           7 SEARCH L6 SSS SAM
L8         111 SEARCH L6 SSS FULL

     FILE 'CAPLUS' ENTERED AT 11:54:56 ON 19 APR 2004
L9          31 L8
               SAVE TEMP L9  DIABETCMPDS/A

=> d l9 10-20 ti

L9   ANSWER 10 OF 31  CAPLUS  COPYRIGHT 2004 ACS on STN
TI   Modulation of bone formation with peroxisome proliferator-activated
     receptor activators and ligands

L9   ANSWER 11 OF 31  CAPLUS  COPYRIGHT 2004 ACS on STN
TI   Peroxisome proliferator-activated receptor subtype-specific regulation of
     hepatic and peripheral gene expression in the Zucker diabetic fatty rat

L9   ANSWER 12 OF 31  CAPLUS  COPYRIGHT 2004 ACS on STN
TI   Method for preparing a model system for cellular insulin resistance and
     device for use with the model system

L9   ANSWER 13 OF 31  CAPLUS  COPYRIGHT 2004 ACS on STN
TI   Preparation of substituted oxazoles and thiazoles as hPPAR alpha
```

activators

L9 ANSWER 14 OF 31 CAPLUS COPYRIGHT 2004 ACS on STN
TI Prevention of plaque rupture by ACAT inhibitors

L9 ANSWER 15 OF 31 CAPLUS COPYRIGHT 2004 ACS on STN
TI Reduction of atherosclerosis in apolipoprotein E knockout mice by activation of the retinoid X receptor

L9 ANSWER 16 OF 31 CAPLUS COPYRIGHT 2004 ACS on STN
TI PPARα agonists inhibit tissue factor expression in human monocytes and macrophages

L9 ANSWER 17 OF 31 CAPLUS COPYRIGHT 2004 ACS on STN
TI Discrete roles for peroxisome proliferator-activated receptor γ and retinoid X receptor in recruiting nuclear receptor coactivators

L9 ANSWER 18 OF 31 CAPLUS COPYRIGHT 2004 ACS on STN
TI Alteration of a single amino acid in peroxisome proliferator-activated receptor-α (PPARα) generates a PPARδ phenotype

L9 ANSWER 19 OF 31 CAPLUS COPYRIGHT 2004 ACS on STN
TI Chemical compounds as selective activators of PPAR alpha

L9 ANSWER 20 OF 31 CAPLUS COPYRIGHT 2004 ACS on STN
TI Preparation of substituted oxazoles and thiazoles as hPPAR gamma and hPPAR alpha activators

=> d 19 19 ti fbib abs

L9 ANSWER 19 OF 31 CAPLUS COPYRIGHT 2004 ACS on STN
TI Chemical compounds as selective activators of PPAR alpha
AN 2000:277947 CAPLUS
DN 132:308064
TI Chemical compounds as selective activators of PPAR alpha
IN Brown, Peter Jonathan; Chapman, James Mood; Oplinger, Jeffrey Alan; Stuart, Ludwig William; Willson, Timothy Mark; Wu, Zhengdong
PA Glaxo Group Ltd., UK; University of South Carolina
SO PCT Int. Appl., 32 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000023407	A2	20000427	WO 1999-GB3420	19991015
	WO 2000023407	A3	20000803		
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
				GB 1998-22473 A	19981016
	AU 9963506	A1	20000508	AU 1999-63506	19991015
				GB 1998-22473 A	19981016
				WO 1999-GB3420 W	19991015
	EP 1149063	A2	20011031	EP 1999-950913	19991015
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				

IE, SI, LT, LV, FI, RO

			GB 1998-22473 A 19981016
			WO 1999-GB3420 W 19991015
	JP 2002527496	T2 20020827	JP 2000-577136 19991015
			GB 1998-22473 A 19981016
			WO 1999-GB3420 W 19991015
	US 6306854	B1 20011023	US 2001-806890 20010416
			GB 1998-22473 A 19981016
			WO 1999-GB3420 W 19991015

OS MARPAT 132:308064
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. [I; m = 0-20; R6 = (un)substituted-cyclohexyl, (un)substituted-Ph,; R8 = (un)substituted-cyclohexyl, (un)substituted-cyclohexylmethyl, (un)substituted-cyclohexylethyl, (un)substituted-Ph, (un)substituted-phenylmethyl, (un)substituted-phenylethyl], ester, salt, physiol. functional derivs., and pharmaceutical composition comprising title compound are prepared and tested as activators of PPAR alpha and used in therapy treating obesity, dyslipidemia, Alzheimer's disease, atherosclerosis, or diabetes. The title compound II was prepared

=> logoff hold

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	61.07	382.53

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-8.32	-9.01

SESSION WILL BE HELD FOR 60 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 13:50:42 ON 19 APR 2004